In May well 2019, a trial at Nanjing University Healthcare facility started evaluating dapagliflozin to liraglutide, and to the anti-diabetic medication acarbose, for their respective results on cognitive and olfactory functionality in 87 overweight men and women whose Kind 2 diabetic issues is badly managed with metformin by itself. [three] https://davidf665yjt8.elbloglibre.com/profile